Genius Sports CEO sells 800K shares, adds collar

Genius Sports’ CEO Mark Locke sold 800,001 shares and established a zero cost collar over 4.4 million shares with strikes at $5.00 and $10.20.

Rhea-AI Filing Summary

Genius Sports Ltd (GENI) disclosed that Chief Executive Officer and director Mark Locke reported several transactions in the company’s Ordinary Shares. On September 15, 16 and 17, 2026 he sold a total of 800,001 Ordinary Shares in open-market transactions at weighted average prices around $6.55 per share, with detailed price ranges noted for the larger blocks.

On September 15, 2026 he also entered into a zero cost collar over 4,400,000 Ordinary Shares, writing European call options with a $10.20 exercise price and purchasing American put options with a $5.00 exercise price, both expiring on September 6, 2028. Only one side of the collar can be in the money at expiration, and the collar will be settled in cash unless he elects physical settlement. No Rule 10b5-1 trading plan is reported in connection with these transactions.

Insider Trade Summary

Net Seller: 800,000 shares

Net Sell 5 txns

Insider Locke Mark

Role Chief Executive Officer

Bought 1 shs

Sold 800,001 shs

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	50,000	$6.541	$327K
Sale	Ordinary Shares F2	272,551	$6.5648	$1.79M
Sale	Call Option (obligation to sell) F3	1	--	--
Purchase	Put Option (right to sell) F3	1	--	--
Sale	Ordinary Shares F1	477,449	$6.5751	$3.14M

Holdings After Transaction: Call Option (obligation to sell) — 1 contracts (Direct); Put Option (right to sell) — 1 contracts (Direct); Ordinary Shares — 19,375,216 shares (Direct)

Footnotes (3)

1. F1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.4663 to $6.7219. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.4998 to $6.6795. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. On September 15, 2026 the Reporting Person entered into a 'zero cost collar' arrangement (the "Transactions") pursuant to which they wrote European call options and purchased American put options over an aggregate 4,400,000 Ordinary Shares. Only one of the options can be in the money on the expiration date, at which time the in-the-money options will be exercised, and the other options will expire. If neither the put options nor the call options are in the money on the expiration date, both will expire. The Transactions will be settled in cash unless the Reporting Person elects physical settlement. The Transactions are 'zero cost collars' in which no premium was exchanged for either the call options or the put options.

Key Figures

Total Ordinary Shares sold: 800,001 shares Sale on September 15, 2026: 477,449 shares at $6.5751 per share (weighted average) Sale on September 16, 2026: 272,551 shares at $6.5648 per share (weighted average) +5 more

8 metrics

Total Ordinary Shares sold 800,001 shares Aggregate of sales on September 15–17, 2026 by the CEO

Sale on September 15, 2026 477,449 shares at $6.5751 per share (weighted average) Open-market sale with trades from $6.4663 to $6.7219

Sale on September 16, 2026 272,551 shares at $6.5648 per share (weighted average) Open-market sale with trades from $6.4998 to $6.6795

Sale on September 17, 2026 50,000 shares at $6.5410 per share Open-market or private transaction as reported

Zero cost collar underlying shares 4,400,000 Ordinary Shares Aggregate shares referenced by the call and put options

Call option exercise price $10.20 per share European call options in the zero cost collar

Put option exercise price $5.00 per share American put options in the zero cost collar

Option expiration date September 6, 2028 Expiration for both collar legs (calls and puts)

Key Terms

zero cost collar, European call options, American put options, weighted average price

4 terms

zero cost collar financial

"entered into a 'zero cost collar' arrangement over an aggregate 4,400,000"

European call options financial

"pursuant to which they wrote European call options over an aggregate"

American put options financial

"and purchased American put options over an aggregate 4,400,000"

weighted average price financial

"The price reported is a weighted average price. These shares were sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did GENI CEO Mark Locke report on this Form 4?

He reported selling 800,001 Ordinary Shares on September 15–17, 2026 at weighted average prices around $6.55 per share, and entering into a zero cost collar over 4,400,000 Ordinary Shares using call and put options expiring September 6, 2028.

How many Genius Sports (GENI) shares did Mark Locke sell and at what prices?

He sold 477,449 shares at a weighted average of $6.5751 on September 15, 272,551 shares at $6.5648 on September 16, and 50,000 shares at $6.5410 on September 17, 2026, totaling 800,001 shares sold.

What is the structure of the zero cost collar reported for GENI by Mark Locke?

On September 15, 2026 he entered a zero cost collar over 4,400,000 Ordinary Shares, writing European call options with a $10.20 exercise price and buying American put options with a $5.00 exercise price, both expiring on September 6, 2028.

How will Mark Locke’s GENI zero cost collar be settled at expiration?

Only one side of the collar can be in the money on the September 6, 2028 expiration date. The in-the-money options will be exercised and the other side will expire. The arrangement is to be settled in cash unless he elects physical settlement.

Was Mark Locke’s trading in GENI shares done under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirming a plan, and the footnotes describe the collar economics but do not state that a Rule 10b5-1 trading plan was used.

What do the price range footnotes mean for the GENI share sales?

For the 477,449 and 272,551 share sales, the reported prices are weighted averages. The actual trades occurred in multiple transactions within stated ranges (for example, about $6.47 to $6.72), and Mark Locke undertakes to provide full breakdowns upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 08:00 PM Accepted by SEC EDGAR 09/17/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Locke Mark

(Last) (First) (Middle)

C/O GENIUS SPORTS LTD

SEYMOUR MEWS HOUSE, 26-37 SEYMOUR MEWS

(Street)

LONDON UNITED KINGDOM W1H 6BN

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Genius Sports Ltd [ GENI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/15/2026		S		477,449	D	$6.5751(1)	19,697,767	D
Ordinary Shares	09/16/2026		S		272,551	D	$6.5648(2)	19,425,216	D
Ordinary Shares	09/17/2026		S		50,000	D	$6.541	19,375,216	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Call Option (obligation to sell)	$10.2	09/15/2026		S/K			1	(3)	09/06/2028	Ordinary Shares	4,400,000	(3)	1	D
Put Option (right to sell)	$5	09/15/2026		P/K		1		(3)	09/06/2028	Ordinary Shares	4,400,000	(3)	1	D

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.4663 to $6.7219. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.4998 to $6.6795. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. On September 15, 2026 the Reporting Person entered into a 'zero cost collar' arrangement (the "Transactions") pursuant to which they wrote European call options and purchased American put options over an aggregate 4,400,000 Ordinary Shares. Only one of the options can be in the money on the expiration date, at which time the in-the-money options will be exercised, and the other options will expire. If neither the put options nor the call options are in the money on the expiration date, both will expire. The Transactions will be settled in cash unless the Reporting Person elects physical settlement. The Transactions are 'zero cost collars' in which no premium was exchanged for either the call options or the put options.

	/s/ Carolyn Duncanson, Attorney-in Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)